Back to search

National and Kapodistrian University of Athens

Επίδραση των πολυμορφισμών του γονιδίου της CETP στη δραστικότητα των υπολιπιδαιμικών φαρμάκων χορηγούμενα στους ίδιους ασθενείς

Abstract

dc:description

Background & Objective. CETP (cholesterol ester transfer protein) is a plasma protein that facilitates the transport of cholesteryl esters and triglycerides between the lipoproteins. It is composed mainly at the liver and it collects triglycerides from chylomicrons and VLDL and exchanges them for cholesteryl esters from HDL. By this mean, very dense LDL molecules are being formed, which are very atherogenetic factors.The gene encoding CETP is located on the long (q) arm of chromosome 16 at position 21. It has been found that at least two polymorphisms in this gene, TaqIB (with B1B1, B1B2 and B2B2 genotypes) and I405V (with II, IV and VV genotypes), have been associated with different response to statin treatment. The aim of this study was to investigate a probable correlation of the aforementioned CETP gene polymorphisms with better or worse response to two specific statins: simvastatin and atorvastatin.MethodsThe DNA of 78 subjects, men and women with dyslipideami, was analyzed for the different genotypes of the CETP gene polymorphisms TaqIB and I405V. To all these patients simvastatin and atorvastatin were administered as lipid lower medications and they had a lipid profil test four times during the study period. Namely, before the beginning of the therapy, two months after taking the first statin (either simvastatin or atorvastatin), two months after they quitted therapy and last two months after restarting the lipid lower therapy taking the other statin.ResultsBoth statins administered to patients succeeded to reduce significantly total cholesterol, triglycerides and LDL-C levels and simultaneously to augment significantly HDL-C levels. These changes have been observed to all patients independently of their genotype of the two studied CETP gene polymorphisms.No significant differences were demonstrated in total cholesterol, triglycerides, HDL-C and LDL-C levels before and after simvastatin and atorvastatin therapy across Taq1B and I405V genotypes.Interpretation & ConclusionThis study confirms the wide-known, that statins play a pivotal role in the treatment of dyslipideamic patients. However, it has not demonstrated significant differences in the lipid profil comparing the different genotypes of the CETP gene polymorphisms TaqIB and I405V with simvastatin and atorvastatin treatment.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2016

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Bousoula, Eleni
  • Μπούσουλα, Ελένη

Subjects

dc:subject × 7

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/37181

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Bousoula, Eleni; Μπούσουλα, Ελένη. Επίδραση των πολυμορφισμών του γονιδίου της CETP στη δραστικότητα των υπολιπιδαιμικών φαρμάκων χορηγούμενα στους ίδιους ασθενείς. National and Kapodistrian University of Athens, 2016. http://hdl.handle.net/10442/hedi/37181